CHRISTIAN PAULSSON IS APPOINTED CEO OF BLUEFISH PHARMACEUTICALS

3 November, 2025 • Press releases

Bluefish Pharmaceuticals has appointed Christian Paulsson as CEO, effective October 31st, 2025. Christian has a solid background as a business leader with more than 25 years of experience from senior positions in both listed and private equity owned companies. He has previously served as CEO, CFO, Head of M&A and board member in several Swedish and international businesses across a range of sectors including health care, retail, e-commerce and manufacturing.

“We are very pleased to announce that Christian who is currently CFO of Bluefish Pharmaceuticals will take on the role as CEO. Christian is well known in the organisation and a business leader with a broad and solid competence. Christian will together with the competent team in Bluefish Pharmaceuticals set the plan for the next phase of growth for the company.”, says Gunilla Spongh, Chairman of the Board of Bluefish Pharmaceuticals.

“Bluefish has earned a strong niche position in European generics. Together with our team, we will focus on sharpening our execution, scaling where we see the best returns, and advancing our pipeline — in order to continue to deliver reliable, affordable medicines to more patients while strengthening profitable growth and prepare the company for future options.”, says Christian Paulsson.

“Annika Muskantor has stepped down from her position as CEO as of October 31st. The decision has been made by mutual agreement with the Board of Directors, and we thank her for her contribution to the company´s development”, says Gunilla Spongh, Chairman of the Board of Bluefish Pharmaceuticals.

For more information contact:

Gunilla Spongh, Chairman of the Board, tel.+46 70 935 25 33

Christian Paulsson, CEO, tel.+46 70 211 00 10, e-mail: christian.paulsson@bluefishpharma.com



Bluefish Pharmaceuticals in brief:

Founded in Sweden in 2005, with its long tradition of industrial entrepreneurship, Bluefish Pharmaceuticals has become one of the most progressive Swedish pharmaceutical companies for generic products. The company focuses exclusively on development and sale of generic drugs. At Bluefish, we strive to make quality medicines accessible to more people. We create value in the full pharmaceutical value chain from developing to successfully marketing generic pharmaceuticals and we take pride in doing this in an innovative, responsible and cost-efficient way. The product portfolio consists of about 80 products and is growing. Bluefish currently conducts operations in 13 countries in Europe. The company has its own development laboratory in Bangalore where we develop our own generic products.



www.bluefishpharma.com

---